Amgen’s Repatha was heralded recently in the media, generating headlines like "New Drug Prevents Heart Attacks in High-Risk Patients." But the company's stock then fell. Who should we believe and why?

Most Medicare drug plans cover Repatha (evolocumab). This includes stand-alone Part D prescription drug plans and Medicare Advantage plans that include prescription drug coverage. Doctors prescribe ...

(Reuters) - Amgen Inc, looking to boost use of its potent cholesterol drug Repatha, has cut the medication's U.S. list price by 60 percent to $5,850, the U.S. biotechnology company said on Wednesday.

Amgen’s cholesterol-fighter Repatha rolled back atherosclerosis in a new clinical trial, showing that the drug doesn’t just push LDL cholesterol down by impressive margins. But the results might not ...

As copycats eat into Amgen’s older products, the big biotech is looking to its newer launches to stem the tide. But some of them are not getting it done. JPMorgan analyst Cory Kasimov name-dropped ...

The maker of an expensive cholesterol drug is slashing the list price, which should make it more affordable for patients. Amgen Inc. said Wednesday it is immediately cutting the price of Repatha by 60 ...

FILE PHOTO: An Amgen sign is seen at the company's office in South San Francisco, California in this October 21, 2013 file photo. REUTERS/Robert Galbraith/Files/File Photo By Deena Beasley (Reuters) - ...

Amgen is cutting the list price of its cholesterol drug Repatha by 60% to $5,850 in an unprecedented move to make the drug available to senior citizens. “We’ve got to make sure those who need [Repatha ...